These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 37809646)

  • 1. Assessing potential surge of COVID-19 cases and the need for booster vaccine amid emerging SARS-CoV-2 variants in Indonesia: A modelling study from West Java.
    Nuraini N; Soekotjo FN; Alifia A; Sukandar KK; Lestari BW
    Heliyon; 2023 Sep; 9(9):e20009. PubMed ID: 37809646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the potential impact of COVID-19 booster doses and oral antivirals: A mathematical modelling study of selected middle-income countries in the Indo-Pacific.
    Bilgin GM; Lokuge K; Munira SL; Glass K
    Vaccine X; 2023 Dec; 15():100386. PubMed ID: 37727365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
    Al Kaabi N; Yang Y; Eldin Hussein S; Yang T; Abdalla J; Wang H; Lou Z; Chinese Center For Disease Control And Prevention ; Bakkour A; Arafat A; China National Biotec Group Company Limited ; Jiang Z; Tian Y; National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd ; Beijing Institute Of Biological Products Company Limited ; Xiao P; Zaher W; Eltantawy I; Wang C; Xu G; Zhang Y; Yang X
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance of the COVID-19 vaccine booster dose and associated factors among the elderly in China based on the health belief model (HBM): A national cross-sectional study.
    Qin C; Yan W; Du M; Liu Q; Tao L; Liu M; Liu J
    Front Public Health; 2022; 10():986916. PubMed ID: 36589991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program.
    Shiri T; Evans M; Talarico CA; Morgan AR; Mussad M; Buck PO; McEwan P; Strain WD
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inequities in COVID-19 vaccine and booster coverage across Massachusetts ZIP codes after the emergence of Omicron: A population-based cross-sectional study.
    Bor J; Assoumou SA; Lane K; Diaz Y; Ojikutu BO; Raifman J; Levy JI
    PLoS Med; 2023 Jan; 20(1):e1004167. PubMed ID: 36719864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of booster vaccination on diphtheria transmission: Mathematical modeling and risk zone mapping.
    Fauzi IS; Nuraini N; Sari AM; Wardani IB; Taurustiati D; Simanullang PM; Lestari BW
    Infect Dis Model; 2024 Mar; 9(1):245-262. PubMed ID: 38312350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study.
    Pascucci D; Grossi A; Lontano A; Marziali E; Nurchis MC; Grassi VM; Raponi M; Vetrugno G; Capelli G; Calabrò GE; Staiti D; Sanguinetti M; Damiani G; Laurenti P
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.
    Puspitasari M; Sattwika PD; Hidayat ARP; Wijaya W; Wardhani Y; Intansari US; Kertia N; Purwanto B; Thobari JA
    BMC Nephrol; 2023 May; 24(1):151. PubMed ID: 37248445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital.
    Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Fathi GC; Widhani A; Aini MH; Yudhistira Y; Azizah S; Rahmadani M; Istanti ND; Giantini A
    Acta Med Acad; 2022 Aug; 51(2):69-78. PubMed ID: 36317998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
    Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
    J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.